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Abstract
Introduction
Hypertension and hyperlipidemia are major cardiovascular dis-
ease risk factors. To modify them, patients often need to adopt
healthier  lifestyles  and  adhere  to  prescribed  medications.
However,  patients’  adherence to recommended treatments  has
been suboptimal.  Reducing out-of-pocket costs (ROPC) to pa-
tients may improve medication adherence and consequently im-
prove health outcomes. This Community Guide systematic review
examined the effectiveness of ROPC for medications prescribed
for patients with hypertension and hyperlipidemia.
Methods
We assessed effectiveness and economics of ROPC for medica-
tions to treat  hypertension,  hyperlipidemia,  or both.  Per Com-
munity Guide review methods, reviewers identified, evaluated,
and summarized available evidence published from January 1980
through July 2015.
Results
Eighteen studies were included in the analysis. ROPC interven-
tions resulted in increased medication adherence for patients tak-
ing blood pressure and cholesterol medications by a median of 3.0
percentage points; proportion achieving 80% adherence to medica-
tion increased by 5.1 percentage points. Blood pressure and cho-
lesterol outcomes also improved. Nine studies were included in
the economic review, with a median intervention cost of $172 per
person per year and a median change in health care cost of  −$127
per person per year.
Conclusion
ROPC for medications to treat hypertension and hyperlipidemia is
effective in increasing medication adherence, and, thus, improv-
ing blood pressure and cholesterol outcomes. Most ROPC inter-
ventions are implemented in combination with evidence-based
health care interventions such as team-based care with medication
counseling. An overall conclusion about the economics of the in-
tervention could not be reached with the small body of inconsist-
ent cost-benefit evidence.
Introduction
High blood pressure and high blood cholesterol (hypertension and
hyperlipidemia, respectively) are 2 major cardiovascular disease
(CVD) risk factors, yet suboptimal treatment of both remains a
persistent problem in the United States. On the basis of recent es-
timates, approximately 31.1 million — or less than half (46.5%)
— of those diagnosed with hypertension have it controlled at re-
commended levels, even though most Americans with hyperten-
sion report having a usual source of health care (89.4%) and health
insurance (85.2%) (1). Although national guidelines do not define
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cholesterol treatment goals, based on earlier guidance, 33% of US
adults with high low-density lipoprotein (LDL) cholesterol did not
have it  controlled at recommended levels (2).  Improvement of
such low control rates is paramount to reducing the prevalence of
CVD in the United States. Because of the aging of the US popula-
tion, the prevalence of all CVD is projected to increase to 40.5%
by 2030, and the total economic burden of CVD is estimated to
exceed $1 trillion annually (3).
One approach to mitigating the rising burden of CVD is through
improved adherence to a regimen of medication, defined as pa-
tients taking medications as prescribed (eg, twice daily) and con-
tinuing to take a prescribed medication (4). Despite pharmaceutic-
al advances to treat CVD risk factors, medication adherence re-
mains suboptimal (5). Adherence to blood pressure medication re-
duces hospitalization risk and health care costs (6); similarly, ad-
herence to statins reduces CVD-related illness and death, but the
medications remain underused. Adherence rates range from 25%
to 40% among older adults (7,8). Cost-related medication nonad-
herence  is  a  serious  problem in  the  United  States,  especially
among vulnerable populations such as older adults and people who
are disabled, uninsured, or underinsured (9,10).
To reduce medication costs, patients often fill fewer prescriptions,
split pills, or skip doses, practices that put them at increased risk
for adverse health outcomes (11). Removing cost-related barriers
by reducing out-of-pocket costs (ROPC) for medications may im-
prove patients’ medication adherence and related health outcomes.
This systematic review examined up-to-date evidence on the ef-
fectiveness and economics of policies and programs that reduce
patient out-of-pocket costs for medications prescribed to treat hy-
pertension, hyperlipidemia, or both. It also assessed the applicabil-
ity of findings for various US populations and considerations for
implementation of ROPC for medications.
For this review, ROPC for patients with hypertension and hyper-
lipidemia involves program and policy changes that make medica-
tions for CVD more affordable. Costs for treatment medications
— generic or brand-name — can be reduced by providing new or
expanded treatment coverage and lowering or eliminating patient
out-of-pocket expenses (eg, copayments, coinsurances, deduct-
ibles). ROPC is coordinated through the health care system with
preventive services delivered in clinical or nonclinical settings (eg,
worksite,  community).  ROPC can be implemented alone or in
combination with additional interventions to enhance patient–pro-
vider interaction such as team-based care, medication counseling,
and patient education. Program or policy changes can be made by
many implementers, including insurance companies, government
agencies, and employers.
Methods
Detailed  systematic  review methods  used by The Community
Guide have been published previously (12,13). For this review, a
review coordination team was formed, comprising CVD subject
matter experts from various agencies, organizations, and academ-
ic institutions, together with qualifıed systematic reviewers from
the Community Guide Branch at the Centers for Disease Control
and Prevention (CDC). The team worked under the oversight of
the independent, unpaid, nonfederal Community Preventive Ser-
vices Task Force. A systematic review of the economic evidence
was conducted along with the effectiveness review. Methods for
conducting Community Guide systematic economic reviews are
available at www.thecommunityguide.org/about/economics.html.
The analytic framework (Figure 1) reflects the team’s conceptual
approach to evaluating evidence on the effectiveness of ROPC to
improve blood pressure and lipid levels. In summary, the team hy-
pothesized that ROPC for patients who have hypertension or hy-
perlipidemia is likely to reduce financial barriers and thereby in-
crease  patient  use  of  CVD preventive  services,  leading  to  in-
creased healthy behaviors and treatment adherence, improved pa-
tient care experience, and ultimately, reduced CVD risk factors,
illness, death, and CVD-related disparities.
Figure  1.  Analytic  framework:  reduced  out-of-pocket  costs  (ROPC)  for
cardiovascular  disease  (CVD)  preventive  services  for  patients  with
hypertension or hyperlipidemia.
 
The economic rationale for ROPC interventions is developed in a
recent article by Baicker and colleagues (14). Copays and coinsur-
ance serve to ensure that the cost to the user is not set so low that
services are overused, the well-recognized problem of moral haz-
ard. Less recognized is that price ought not to be set so high that
users consume less than what is medically recommended, what
Baicker and colleagues call behavioral hazard. These consumer
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behaviors are leveraged in interventions that seek to set out-of-
pocket costs optimally, so users are motivated to use the recom-
mended  amounts.  Value-based  insurance  design  (VBID)  pro-
grams go farther by targeting the reductions in cost to users to
those at higher risk and by reducing the relative cost to users of al-
ternatives that are more effective or as effective but cheaper. Plans
implement these interventions because the increased high-value
health-related consumption averts more serious and expensive-to-
treat diseases and conditions. Baicker and colleagues did not in-
clude patient income as an explanatory variable in their models.
However, a recent study (15) and earlier findings from the Rand
Health Insurance Experiment (HIE) (16) corroborate that the re-
sponse to changes in out-of-pocket cost do not vary substantially
across income levels.
This economic review takes a plan perspective, in which the cost
of the program would include the cost to cover what was previ-
ously paid by the user and the cost  of providing the increased
quantity demanded by users facing a lower price. The benefits
would be averted long-term health care costs due to improved
health of the insured. Additionally, because the plan has to pay for
and implement these programs, the financial viability of the inter-
ventions is central to their likelihood of implementation.
Databases searched for this review were Cochrane, EBSCOhost,
EMBASE, Web of Science, Gateway, MEDLINE/PubMed, and
ProQuest. The search period was January 1980 to July 2015. A
concurrent search was conducted for studies that provided eco-
nomic information about these interventions, with the addition of
specialized databases maintained in CRD York and EconLit.
Reference lists of articles reviewed, as well as lists in reviewed
articles, were searched, and subject matter experts were consulted.
The complete search strategy is available at www.thecommunity-
guide.org/cvd/supportingmaterials/index.html.
Studies were included as a source of evidence for this review if
they 1) were published in English; 2) were conducted in a high-in-
come country as classified by The World Bank (17); 3) had the
following study designs: randomized controlled trials (RCTs), a
design  with  a  concurrent  comparison  group,  uncontrolled
before–after, or post-only with a comparison group; 4) reported at
least one blood pressure or lipid outcome; 5) had 50% or more of
the study population with dyslipidemia or primary hypertension,
regardless of other CVD risk factors (eg, diabetes); and 6) had less
than 50% of the study population with a history of cardiovascular
events.
Each study that met the inclusion criteria was screened by 2 re-
viewers using standard Community Guide criteria; study data were
abstracted and assessed for suitability of design using the standard
abstraction form (www.thecommunityguide.org/methods/abstrac-
tionform.pdf) (13). Data were collected on outcomes of interest,
participant demographics, intervention characteristics, applicabil-
ity/generalizability, additional benefits, potential harms, considera-
tions  for  implementation,  and  evidence  gaps.  Disagreements
between reviewers were reconciled by consensus.
Suitability of study design was classified as greatest, moderate, or
least. Studies that collected data on intervention and comparison
populations prospectively were classified as having greatest suit-
ability  of  design.  Those  that  collected  data  retrospectively  or
lacked a comparison group but conducted multiple pre–post meas-
urements had moderate design suitability. Studies without a com-
parison group providing before and after measurements had least
suitable designs.
Threats to validity, such as poor descriptions of the intervention,
population, sampling frame, and inclusion/exclusion criteria; poor
measurement of exposure or outcome; poor reporting of appropri-
ate analytic methods; loss to follow-up; or intervention and com-
parison groups not  being comparable at  baseline were used to
characterize studies as having good, fair, or limited quality of exe-
cution. Studies with limited quality of execution were excluded
from analysis.
Medication adherence was assessed by using 2 outcomes: change
in proportion of patients adhering to prescribed medications for
hypertension or hyperlipidemia, measured by using medication
possession ratio, and change in proportion of patients achieving a
high level of adherence, typically those who refill  and possess
medication 80% of the time (18).
The minimum requirements for this  outcome were established
standards for blood pressure control as of 2012 (<140/90 mm Hg
[systolic/diastolic] or <130/80 mm Hg for people with diabetes)
(19). For each study, using data from the last available point in an
ongoing intervention, the team calculated the absolute (percentage
point) change in the proportion of patients receiving ROPC who
achieved blood pressure control compared with a reference group
or pre-ROPC value.
For each study, the effect estimate for change in mean systolic
blood pressure (SBP), diastolic blood pressure (DBP), low-dens-
ity lipoprotein (LDL) cholesterol, triglycerides, and total choles-
terol was calculated by using the last available point in an ongo-
ing intervention for patients receiving ROPC compared with a ref-
erence group or pre-ROPC value. Outcomes pertaining to illness
and death were collected and analyzed when reported.
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Because study designs and reporting of outcomes for medication
adherence were heterogeneous, conducting a meta-analysis was
not appropriate. Therefore, descriptive statistics that facilitated
simple and concise summaries of study result distribution were
used for primary and secondary outcomes.
Individual effect estimates were calculated for each outcome. Per-
centage point (PP) changes were calculated for medication adher-
ence and for the following at goal: blood pressure, LDL cholester-
ol, total cholesterol, and hemoglobin A1c (A1c). Absolute mean
differences were calculated for change in mean SBP, DBP, total
cholesterol, LDL cholesterol, triglycerides, A1c, and fasting blood
glucose. For overall summary measures, the median of effect es-
timates from individual studies and interquartile intervals (IQIs)
were  reported  for  each  outcome based  on  suitability  of  study
design. IQIs were calculated when the body of evidence included
more than 4 studies; otherwise, ranges were reported.
Results
After screening 11,418 titles and abstracts, we selected 47 studies
for full-text review; 18 studies met inclusion criteria (20–37) (Fig-
ure 2). One study was excluded for limited quality of execution
(38) and 3 provided information on an already-included study
(39–41).  Details  of  the  included  studies  are  available  at
www.thecommunityguide.org/cvd/supportingmaterials/IS-
ROPC.html.
Figure 2. Flow diagram, showing number of studies identified, reviewed in full
text,  reasons  for  exclusion,  and  total  number  of  included  studies.
Abbreviation: ROPC, reducing patient out-of-pocket costs.
 
Of the 18 included studies  (20–37),  15 were conducted in the
United States (20,21,23–25,27–31,33–37), one in Israel (26), one
in Italy (22), and one in Australia (32). All studies evaluated pro-
grams or policies that implemented ROPC for medications to treat
patients with hypertension, hyperlipidemia, or both. Moreover, 7
o f  t h e  1 8  i n c l u d e d  s t u d i e s  u s e d  a  V B I D  p l a n
(24,25,27,28,33,34,37) and 3 studies used pharmaceutical medica-
tion assistance programs (PMAP) programs to procure medica-
tions for indigent patients (29,35,36). Although most studies also
implemented medication counseling or patient education, they did
not report ROPC for these services. Seven studies used a team-
based  care  approach  combined  with  medication  counseling
(21,23,24,29,30,35,36); 7 studies also evaluated interventions that
eliminated medication costs but did not specify if  medications
were generic or brand name (20–22,26,29,30,35). Nine studies
provided generic medications free of charge and brand name med-
ications at reduced cost (23–25,27,32–34,36,37), and one evalu-
ated reduced coinsurance (cost for covered benefits the insured
pays after the deductible has been paid) (28).
Most studies reported implementing ROPC for medications with
one or more health care intervention components, such as medica-
tion counseling. Two studies (20,26) did not report implementing
specific health care interventions — such as medication counsel-
ing — with ROPC, although it is unlikely that patients in these
studies received ROPC for medication without receiving a new or
existing health care intervention (eg, patient education).
Study populations primarily included working-age adults (median
age 54.7 y) with more women than men participating (Table 1).
Studies included diverse racial/ethnic groups, which were predom-
inantly  white  in  3  studies  (20,23,37),  African  American  in  2
(21,30), and Hispanic in one (29). Patients in 12 studies were fully
insured (20,22–25,27,28,31–34,37); patients in 7 of those studies
were fully insured under a VBID plan (24,25,27,28,33,34,37). Six
studies included mostly uninsured or underinsured low-income pa-
tients (21,26,29,30,35,36).
Seven studies evaluated the effectiveness of ROPC on patients’
medication adherence, measured as the percentage of time a pa-
t i en t  i s  in  possess ion  o f  a  p resc r ibed  med ica t ion
(24,25,27,28,33,34,37) (Table 2). All 7 studies evaluated patients
in VBID plans.  Six studies measured overall  adherence for 15
blood pressure and lipid medications, and found adherence rates
increased by a median of 3.0 percentage points (IQI = 2.3, 4.5
PPs). The remaining VBID study reported a 5.1 percentage point
increase in the proportion of patients achieving 80% adherence to
blood pressure medications (28).
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Two studies examined adherence in non-VBID populations using
different measurements for adherence. One study — in a non-
VBID population — reported that medication adherence increased
by 21.4 percentage points among those with low baseline adher-
ence (<55%) but decreased by 2.2 percentage points among those
with high baseline adherence (22). Another study, conducted in
Australia, found that patients who did not hold a concession card,
which reduced out-of-pocket costs, were 1.63 times more likely to
be nonadherent to statin therapy (32).
The results for blood pressure (Table 2) are based on suitability of
design.  For  studies  reporting proportion of  patients  with  con-
trolled blood pressure, 3 studies with greatest or moderate design
suitability showed a median improvement of 6.0 percentage points
(30,31,36); 4 studies with least suitable designs reported a median
improvement of 30.1 percentage points (IQI = 20.3, 46.5 PPs)
(20,21,23,37). For change in SBP, 4 studies with greatest or mod-
erate design suitability reported a median reduction of 5.9 mm Hg
(29–31,36). Six studies with least suitable designs had a median
reduction  of  8.7  mm  Hg  (IQI  =  –14.5,  –5.45  mm  Hg)
(20,21,23,26,35,37). Similarly, for change in DBP, 4 studies with
greatest or moderate design suitability reported a median reduc-
tion  of  3.75  mm Hg (29–31,36);  6  studies  with  least  suitable
designs reported a median reduction of 4.5 mm Hg (IQI = –7.8,
–3.8 mm Hg) (20,21,23,26,35,37).
Blood pressure outcomes among low-income populations.  Six
studies reported blood pressure outcomes among majority low-in-
come patient populations; 3 had greatest or moderate suitability of
design  (29,30,36)  and  3  had  least  suitable  study  designs
(21,26,35). Two of 3 studies with greatest or moderate suitability
reported proportion of patients with blood pressure controlled; the
median improvement was 4.4 percentage points (range = –8.2,
17.0 PPs) (30,36). Only one study with least suitable design repor-
ted blood pressure control, with an overall improvement of 51 per-
centage points (21). All 6 studies reported mean changes in SBP
and  DBP.  For  3  studies  of  greatest  and  moderate  suitability
(29,30,36), the median reductions were 10 mm Hg (range = –10.9,
5.7 mm Hg) and 5 mm Hg (range = –6.4, –2.5 mm Hg), respect-
ively; the 3 studies of least suitable design reported median reduc-
tions of  8  mm Hg (range = –24.8,  2.0  mm Hg) and 6 mm Hg
(range = –13.1, –3.2 mm Hg), respectively (21,26,35).
Value-based Insurance Design. Only one study reported clinical
outcomes for fully insured patients with a VBID plan (37). That
study reported an increase of 18.0 percentage points for propor-
tion of patients with blood pressure controlled. Changes in mean
SBP and DBP were mean reductions of 6.6 mm Hg and 4.2 mm
Hg, respectively.
Pharmaceutical medication assistance programs. Three studies fo-
cused on reported outcomes for blood pressure in PMAP popula-
tions (29,35,36). For proportion of patients with blood pressure at
goal, one study reported an unfavorable decrease of 8.2 percent-
age points (36). All 3 studies reported outcomes for SBP and DBP.
Two studies with greatest and moderate suitability of design repor-
ted median reductions of 2.15 mm Hg and 3.75 mm Hg, for SBP
and DBP respectively (29,36); one study with least suitable design
reported mean reductions of 2.0 mm Hg and 6.0 mm Hg, respect-
ively (35).
Results for 6 studies (Table 2) evaluated ROPC effects on lipid
outcomes  in  target  populations,  including  VBID  and  PMAP
(23,26,29,35–37). ROPC interventions were effective in improv-
ing change in total cholesterol, LDL cholesterol, and triglycerides.
Favorable results were also reported for proportion of patients
with LDL cholesterol at goal, although one study reported unfa-
vorable results for total cholesterol at goal (30).
Additional Evidence
Illness and death outcomes. Two studies assessed ROPC effects
on illness or death (22,23). One employer-initiated study reported
significant reductions in rate of myocardial infarction (odds ratio
[OR] = 0.24; 95% confidence interval [CI], 0.098–0.594) and any
CVD events (OR = 0.47; 95% CI, 0.328–0.671) during the inter-
vention period compared with the historical period (23). The other
study reported that among patients with low baseline adherence
(<55%), hospitalization rates decreased from 7.9% to 7.0% and
mortality rates decreased from 3.4% to 3.2%; both reductions were
significant at P < .05 (22).
The economic search identified 9 studies for inclusion in the eco-
nomic review (23,26,28,33,34,37,40,42,43), of which 7 were eval-
uations of VBID programs (28,33,34,37,40,42,43). All the studies
evaluated interventions that reduced the cost of medications (Ta-
ble 3). Interventions in addition to ROPC were reported in 5 of the
studies, 2 with team-based care (23,37) and 3 with disease or life-
style management offered in addition to VBID benefits (28,34,43).
Only one study targeted a low-income population (26). No studies
reported cost-effectiveness of the intervention. All monetary val-
ues reported are in 2014 US dollars, using the Consumer Price In-
dex  from the  Bureau  of  Labor  Statistics  (44)  and  purchasing
power parities from the World Bank for conversions (45).
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The intervention cost per person per year of increased pharmacy
spending by plans was provided by all 9 studies, with median =
$172 (IQI: $70 to $529, n = 10). The higher estimates included
blood pressure-lowering and diabetes medications. Of the 5 stud-
ies  that  had interventions  in  addition to  ROPC,  only  one also
provided the cost of the additional team-based care component
(37).
Seven studies estimated change in health care cost, with median =
–$127 (IQI: –$632 to –$18, n = 8) (23,28,33,34,37,40,43), where
all but 2 included interventions in addition to ROPC (33,40). In
the context of these multiple intervention studies, the observed ef-
fects on health outcomes and health care cost result from the com-
bined interventions rather than ROPC alone. The follow-up peri-
od for these studies ranged from 1 year to 5 years, with most last-
ing from 1 to 2 years, inclusive.
The elasticity of medication adherence could not be calculated for
the included studies because either the information was not avail-
able or the change in adherence was due to interventions in addi-
tion to ROPC.
Of 3 studies that reported sufficient information to compute net
benefits, 2 found the cost of intervention exceeded averted health
care costs by $337 (37) and $90 (40) per patient per year, and the
third found the intervention to be cost-neutral (33). Hence, the
evidence for net benefit is mixed and, in particular, the 2 studies
that were not combined interventions indicate VBID was cost-
neutral in one instance (33) and cost-increasing in another (40).
Discussion
Findings from this review are applicable to the US health care sys-
tem and working-age adults. Although patients from both sexes
and diverse racial and ethnic groups were well represented, evid-
ence from this review indicates that ROPC is especially beneficial
for low-income patients. Moreover, ROPC interventions are ap-
plicable to diverse policy and program implementers, such as em-
ployers and government agencies.
Coordination of ROPC with additional interventions (eg, medica-
tion counseling) may increase opportunities for patient–provider
interaction  on  treatment  issues  (eg,  medication  side  effects).
Neither the included studies nor the broader literature identified
any harms to patients from these interventions.
According to Community Guide rules of evidence (12), there is
strong evidence that ROPC for medications to treat hypertension
and hyperlipidemia is effective in 1) improving medication adher-
ence and 2) improving blood pressure and cholesterol outcomes,
when implemented in combination with evidence-based health
care interventions such as team-based care with medication coun-
seling. However, an overall conclusion cannot be reached regard-
ing the economics of the intervention from the small body of in-
consistent evidence on net benefits.
This review examined effectiveness of ROPC for medications to
treat hypertension and hyperlipidemia. Findings are consistent
with those from an Agency for Healthcare Research and Quality
(AHRQ) systematic review of interventions to improve medica-
tion adherence for chronic diseases (46). The broader review iden-
tified 5 studies that examined ROPC for patients with CVD. Be-
cause our review focused on CVD prevention (ie, hypertension,
hyperlipidemia), it excluded some studies included in the AHRQ
review; nonetheless, both reviews reached a similar conclusion
despite having different inclusion criteria. To the authors’ know-
ledge, this is the only systematic review focused on CVD preven-
tion to examine the relationship between cost-sharing and medica-
tion adherence in patients with hypertension and hyperlipidemia.
The  impact  of  patient  cost-sharing  was  first  assessed  in  the
groundbreaking  study,  the  RAND  HIE,  conducted  during
1971–1982 (16). Although the HIE results have influenced many
insurance plans’ cost-sharing policies for office visits for prevent-
ive services, evidence for cost-sharing on prescription drug plans
is still  sparse, especially for chronic disease management. The
body of evidence in this review — albeit small — indicates that
progress has been made in evaluating the impact of cost-sharing
on medication adherence in people with chronic diseases. Of 18
studies included in this review, only 2 were published before 2000
(20,31); this trend appears to be the same for the 5 ROPC studies
in the AHRQ review (46). The team postulates that the lack of
studies before 2000 could be due to several factors: the focus of
this review on CVD prevention; financing model of prescription
medications in earlier years (eg, cash only); changes in insurance
designs (eg, medical insurance plus prescription drug plans); or
possible publication bias during 1980–2000.
Implementation of ROPC interventions primarily has implications
for health policy decision makers considering changes to health in-
surance and prescription drug plans. Several opportunities exist for
innovative application of ROPC programs and policies. Ideally,
ROPC for hypertension and hyperlipidemia treatment will be im-
plemented along with other CVD preventive services. A compre-
hensive approach might coordinate ROPC for medications to treat
hypertension and hyperlipidemia with ROPC for evidence-based
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treatments of tobacco cessation (47) and management of patients
with diabetes. Additionally, prescribing providers or others in the
health care system can be advocates for their patients by 1) act-
ively asking patients about their ability to pay for medications and
2) familiarizing themselves with medications covered by patients’
health insurance plans with no or low out-of-pocket costs to pa-
tients. A more complete discussion of considerations for imple-
mentation is available (48).
This review has several limitations. The quality of included stud-
ies varies, with only 2 RCTs. Because ROPC interventions tend to
be policy-based, a broad approach was taken to include observa-
tional study designs, thus allowing assessment of these interven-
tions in real-world,  practice-based settings.  However,  because
most included studies were observational, the validity of this re-
view may be threatened by biases associated with observational
studies (eg, confounding, selection bias), leading to intervention
effects in a favorable direction. Furthermore, because of hetero-
geneity in study designs and reporting of outcomes for medication
adherence, a meta-analysis was not conducted; hence, descriptive
statistics were used to summarize findings of this review. Visual
inspection of funnel plots examining the relationship between ef-
fect size and sample size indicated possible publication bias for
clinical and medication adherence outcomes, with most outcomes
reporting favorable results.
Future studies should report whether health improvements are dir-
ectly associated with incremental  reductions in patient  out-of-
pocket costs and describe ROPC effects on both medication adher-
ence and clinical outcomes. Furthermore, natural experiments are
needed to comparatively evaluate the impact ROPC interventions
have on medication adherence, clinical outcomes, and health beha-
vior outcomes. Lack of reporting also precluded the team from
evaluating how access to medication influenced medication adher-
ence, although it can be assumed that PMAP made brand-name
medications readily  accessible  to  indigent  patients.  Future  re-
search should also investigate the impact of cost-sharing and med-
ication adherence on high-income socioeconomic groups, where
the marginal cost-share difference is expected to be a smaller pro-
portion of total income.
The absence of cost-effectiveness evaluations of these interven-
tions needs to be addressed in future research. Furthermore, eco-
nomic evaluations should provide the cost of implementing both
the ROPC and the additional intervention when ROPC is com-
bined with interventions such as team-based care.
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Tables
Table 1. Studies (N = 18) Reporting Population Characteristics for Interventions That Reduce Patient Out-of-Pocket Costs for Med-
ications to Treat Hypertension and Hyperlipidemia, January 1980 to July 2015
Characteristic Category Number of Studies Reporting Characteristic (% of total)a
Age, y
Adult (18–64) 10 (56)
Older adults (>64) 4 (22)
Sex
Majority female 12 (67)
Majority male 3 (17)
Race/Ethnicity
Majority white 3 (23)
Majority African American 2 (15)
Majority Hispanic 1 (8)
Income level Majority low-income 6 (46)
Type of benefit designb
Fully insured 12 (67)
Fully insured under VBID 7 (39)
Underinsured/uninsured 6 (46)
Abbreviations: VBID, value-based insurance design.
a Total number of studies (and proportion) that reported specific demographic characteristic. Because some studies provide no information on variable of interests,
totals do not add up to 100%.
b Categories are not mutually exclusive.
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Table 2. Effects of Reducing Patient Out-of-Pocket Costs for Medications to Treat Hypertension and Hyperlipidemia on Medication
Adherence, Blood Pressure Outcomes, and Lipid Outcomes in 9 Studies Published From January 1980 Through July 2015
Review Outcome Effectiveness Measurements
Suitability of Study Design (No. of
Studies) Summary Estimates
Medication adherence
PP change in patient adherence rates for
blood pressure and cholesterol
medications
Greatest (6 studies with 15 study
medications) (24,25,27,33,34,37)
Median: increase of 3.0 PPs
(IQI, 2.3 to 4.5 PPs)
PP change in proportion of patients
achieving 80% adherence
Greatest (1 study) (28) Increase of 5.1 PPs
Blood pressure (BP) at
goal
PP change in proportion of patients with
controlled BP
Greatest or moderate (3 studies)
(30,31,36)
Median: increase of 6.0 PPs
(range,−8.2 to 17 PPs)
Least (4 studies) (20,21,23,37) Median: increase of 30.1 PPs
(IQI, 20.3 to 46.5 PPs)
Systolic blood pressure
(SBP) Change in mean SBP (mm Hg)
Greatest or moderate (4 studies
(29–31,36)
Median: decrease of 5.9 mm Hg
(range, –10.7 to 3.83 mm Hg)
Least (6 studies) (20,21,23,26,35,37) Median: decrease of 8.7 mm Hg
(IQI, −14.5 to –5.45 mm Hg)
Diastolic blood pressure
(DBP) Change in mean DBP (mm Hg)
Greatest or moderate (4 studies)
(29–31,36)
Median: decrease of 3.75 mm
Hg (range, –6.1 to –2.1 mm Hg)
Least (6 studies) (20,21,23,26,35,37) Median: decrease of 4.5 mm Hg
(IQI, –7.8 to –3.8 mm Hg)
Low-density lipoprotein
(LDL) cholesterol
Change in mean LDL cholesterol (mg/dL)
Greatest or moderate (3 studies)
(29,36,37)
Median: reduction of 14 mg/dL
(range, –16 to –6.9 mg/dL)
Least: (3 studies) (23,26,35) Median: reduction of 14 mg/dL
(IQI, –18.9 to 10.9 mg/dL)
 PP  change in proportion of patients
achieving LDL cholesterol goal
Greatest or moderate (2 studies)
(36,37)
Median: increase of 18.5 PPs
(range, 13 to 24 PPs)
Least (1 study) (23) Increase of 10 PPs
Triglycerides (TG) Change in mean TG (mg/dL)
Greatest or moderate (2 studies)
(29,37)
Median: reduction of 11.4 mg/
dL (range, –13.0 to –9.8 mg/
dL)
Least (2 studies) (23,35) Median: reduction of 31.7 mg/
dL (range, –38.4 to 25.0 mg/
dL)
Total cholesterol (TC)
Change in mean TC (mg/dL)
Greatest (1 study) (29) Reduction of 15 mg/dL
Least (1 study) (35) Reduction of 25 mg/dL
PP change in proportion of patients
achieving TC goal
Greatest (1 study) (30) Decrease of 7.0 PPs
Abbreviations: IQI, interquartile interval; PP, percentage points.
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Table 3. Intervention Cost, Health Care Cost, and Net Benefit of Reducing Patient Out-of-Pocket Costs (ROPC) for Medications to
Treat Hypertension and Hyperlipidemia in 9 Studies Published From January 1980 Through July 2015
Study
Size of
Intervention
Group, Length of
Follow-up VBID
Cost of ROPC for
Medications Per
Patient Per Year
Cost of Other
Intervention
Components Per
Patient Per Year
Health Care Cost Per
Patient Per Year
(Components)
Net Benefit Per
Patient Per
Year
Bunting et al
2008 (23)
N = 620, 5 y No $676 TBC: NR −$759 (OP, IP, ER) NR
Elhayanya,b and
Vinker 2011 (26)
N = 938, 1 y No $642 NA NR NR
Wertz et al 2012
(37)
N = 307, 14 mos Yes $45 TBC: $541 −$249 (OP, IP, ER) −$337
Gibson et alc
2011 (28)
N = 2,873, 2 y Yes $78 Disease management:
NR
−$2,417 Yr 1, −$4,240
Yr 2 (OP, IP)d
NR
Kelly et al 2009
(40)
N = 1,550, 2 y Yes $205 NA −$114 (OP, IP, ER) −$90
Chernew et alb
2010 (42)
NR, NR Yes $116 NA NR Modeled
assumptions
suggest that
VBID is cost-
neutral
Choudhry et al
2012 (43)
N = 2,051, 1 y Yes $16 Disease management:
NR
$14 (OP, IP, ER, Long-
term care)d
NR
Maciejewski et al
2014 (33) N = 750,000, 1 y Yes $153–$190 NA
Patients with high blood
pressure only: −$158 in
year 1 and −$74 in year
2
$0, cost-neutralPatients with high blood
pressure and
hyperlipidemia: −$160
in year 1 and −$116 in
year 2 (OP, IP, ER)d
Musich et al 2015
(34)
N = 2,674, 2 y Yes Patients with high
blood pressure: $491
Disease/lifestyle
management
coaching: NR
Patients with high blood
pressure: $376 (OP, IP)d
NR
Abbreviations: ER, emergency department; IP, inpatient; NA, not applicable; NR, not reported; OP, outpatient; ROPC, reduced out-of-pocket costs; TBC, team-based
care; VBID, value-based insurance design.
a Study conducted in Israel; all other studies were conducted in the United States.
b Study targeted low-income patients.
c Includes blood pressure, cholesterol, diabetes, and asthma medications covered under VBID.
d Compared with control.
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